Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Predictive Toxicology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1584734

Bridging the gaps in detection of structural cardiotoxicity in stem cellderived cardiomyocytes: promise of miR-133, miR-184 and miR-208-3p

Provisionally accepted
  • 1University of Antwerp, Antwerp, Antwerp, Belgium
  • 2UCB Biopharma SPRL, Brussels, Belgium

The final, formatted version of the article will be published soon.

Drug-induced cardiotoxicity is one of the main causes of attrition due to safety in preclinical and clinical development; therefore, identifying novel assays and/or biomarkers to detect potentially harmful candidates is pivotal for the pharmaceutical industry. Over the past decade, microRNAs (miRNAs) have been proposed as alternative translatable biomarkers for cardiotoxicity. Although miRNAs could be useful for detection of cardiotoxicity, they are not routinely assessed in preclinical drug development.The current study aimed to investigate dysregulation of miRNAs in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and their culture media after exposure to a set of cardiotoxic agents known to cause structural cardiotoxicity by different mechanisms of action. Dose-response analysis of intracellular miRNA expression was conducted after 72-hour incubation with 29 drugs, while the presence of miRNAs in the culture media was evaluated at 24-, 48-, and 72-hour posttreatment in response to 7 selected treatments. As a result, we confirmed the upregulation of the following intracellular miRNAs across various drug classes: hsa-miR-96-5p, hsa-miR-126-3p, hsa-miR-133b, hsa-miR-146b-5p, hsa-miR-182-5p, hsa-miR-187-3p and hsa-miR-365a-5p. Interestingly, miRNAs expression in the cell culture media represented different patterns and magnitudes of upregulation, compared to the intracellular miRNAs. hsa-miR-133b, hsa-miRNA-184 and hsa-miR-208b-3p were found to be upregulated the most in the cell culture media. The combination of intracellular and secreted miRNAs in hiPSC-CM might expand the tools for early identification of structural cardiotoxicity in preclinical drug discovery and provide a potential link to circulating miRNAs in patients with drug-induced cardiotoxicity.

Keywords: hiPSC-CM, structural cardiotoxicity, biomarkers, miRNA, cardiotoxicity

Received: 27 Feb 2025; Accepted: 07 Jul 2025.

Copyright: © 2025 Cherubin, Delaunois, Valentin, Alaerts, Guns and Gryshkova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Vitalina Gryshkova, UCB Biopharma SPRL, Brussels, Belgium

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.